Hepatitis D (HDV) - Drug Pipeline Landscape, 2023
Description
Hepatitis D (HDV) - Drug Pipeline Landscape, 2023
Hepatitis D, also known as delta hepatitis, is an inflammation of the liver caused by the hepatitis D virus (HDV), which requires HBV for its replication. Hepatitis D infection cannot occur in the absence of hepatitis B virus. HDV-HBV co-infection is considered the most severe form of chronic viral hepatitis due to more rapid progression towards hepatocellular carcinoma and liver-related death.
The primary route of transmission for hepatitis D is contact with infected blood or other bodily fluids. This can happen through sharing needles or drug materials with an infected person or having unprotected sex with an infected person. The signs and symptoms of HDV can include: yellow skin and eyes (jaundice), stomach upset, pain in your belly, throwing up, fatigue, loss of appetite, joint pain, dark urine, light-colored stool.
Diagnosis includes bloodwork and imaging tests to check liver for signs of damage. To make an accurate diagnosis, doctor will perform a blood test that can detect anti-hepatitis D antibodies in the blood. There may be additional tests to determine if there is liver damage as a result of hepatitis D. The tests can include: An elastography and A liver biopsy.
Medications are not effective against acute hepatitis D; the acute infection tends to subside on its own. As for chronic hepatitis D, appropriate treatment depends on the phase of the disease and how severe the infection is. If a person's liver is severely damaged, a liver transplant may become necessary. Doctors may prescribe a drug called interferon alfa or, alternatively, one called pegylated interferon alpha, for chronic hepatitis D.
The companies that are active in the development of HDV drugs. Some of them include, Antios Therapeutics, Inc, Eiger BioPharmaceuticals, Gilead Sciences, Inc., Hepatera Ltd, Merck & Co., Inc etc.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Hepatitis D treatment such as Bulevirtide, Lonafarnib, Peginterferon Lambda-1A and others. Key players involved in the development of therapies to treat Hepatitis D are Antios Therapeutics Inc, Eiger BioPharmaceuticals, Janssen Research & Development LLC, PharmaEssentia, Vir Biotechnology Inc and others. Three drugs are under late-stage Phase III clinical trials and six drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
Report Highlights
Global Insight Service's, Hepatitis D (HDV) - Drug Pipeline Landscape, 2023 report provides an overview of the Hepatitis D pipeline drugs. This report covers detailed insights on Hepatitis D (HDV) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Hepatitis D (HDV) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
To plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Hepatitis D, also known as delta hepatitis, is an inflammation of the liver caused by the hepatitis D virus (HDV), which requires HBV for its replication. Hepatitis D infection cannot occur in the absence of hepatitis B virus. HDV-HBV co-infection is considered the most severe form of chronic viral hepatitis due to more rapid progression towards hepatocellular carcinoma and liver-related death.
The primary route of transmission for hepatitis D is contact with infected blood or other bodily fluids. This can happen through sharing needles or drug materials with an infected person or having unprotected sex with an infected person. The signs and symptoms of HDV can include: yellow skin and eyes (jaundice), stomach upset, pain in your belly, throwing up, fatigue, loss of appetite, joint pain, dark urine, light-colored stool.
Diagnosis includes bloodwork and imaging tests to check liver for signs of damage. To make an accurate diagnosis, doctor will perform a blood test that can detect anti-hepatitis D antibodies in the blood. There may be additional tests to determine if there is liver damage as a result of hepatitis D. The tests can include: An elastography and A liver biopsy.
Medications are not effective against acute hepatitis D; the acute infection tends to subside on its own. As for chronic hepatitis D, appropriate treatment depends on the phase of the disease and how severe the infection is. If a person's liver is severely damaged, a liver transplant may become necessary. Doctors may prescribe a drug called interferon alfa or, alternatively, one called pegylated interferon alpha, for chronic hepatitis D.
The companies that are active in the development of HDV drugs. Some of them include, Antios Therapeutics, Inc, Eiger BioPharmaceuticals, Gilead Sciences, Inc., Hepatera Ltd, Merck & Co., Inc etc.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Hepatitis D treatment such as Bulevirtide, Lonafarnib, Peginterferon Lambda-1A and others. Key players involved in the development of therapies to treat Hepatitis D are Antios Therapeutics Inc, Eiger BioPharmaceuticals, Janssen Research & Development LLC, PharmaEssentia, Vir Biotechnology Inc and others. Three drugs are under late-stage Phase III clinical trials and six drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
Report Highlights
Global Insight Service's, Hepatitis D (HDV) - Drug Pipeline Landscape, 2023 report provides an overview of the Hepatitis D pipeline drugs. This report covers detailed insights on Hepatitis D (HDV) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Hepatitis D (HDV) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
To plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
78 Pages
- 1. Introduction
- 1.1 Hepatitis D - Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview - Hepatitis D
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Hepatitis D - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs-Filing Rejected
- 5.1.1 Bulevirtide
- 5.2 Clinical Stage Drugs-Phase III
- 5.2.1 Lonafarnib
- 5.2.2 Peginterferon Lambda-1A
- 5.2.3 PEG IFN alfa-2a
- 5.3 Clinical Stage Drugs-Phase II
- 5.3.1 JNJ-73763989
- 5.3.2 ATI-2173
- 5.3.3 REP 2139-Ca
- 5.3.4 REP 2139-Mg
- 5.4.5 VIR-2218
- 5.4.6 VIR-3434
- 5.4 Clinical Stage Drugs-Phase I
- 5.4.1 Ropeginterferon alfa-2b
- 5.5 Clinical Stage Drugs-Preclinical
- 5.5.1 Pres1-WHc VLPs
- 5.5.2 GNV705
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Antios Therapeutics, Inc
- 9.2 Eiger BioPharmaceuticals
- 9.3 Gilead Sciences
- 9.4 Hepatera Ltd.
- 9.5 Janssen Research & Development, LLC
- 9.6 PharmaEssentia
- 9.7 Replicor Inc.
- 9.8 Vir Biotechnology, Inc.
- 9.9 VLP Biotech
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1.1 Number of Products under Development by Hepatitis D
- Table 1.2 Number of Products under Development by Companies
- Table 1.3 Products under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 2.1 Clinical Trial Details – Bulevirtide/Gilead Sciences
- Table 2.2 Clinical Trial Details – Lonafarnib/Eiger BioPharmaceuticals
- Table 2.3 Clinical Trial Details – Peginterferon Lambda-1A/Eiger BioPharmaceuticals
- Table 2.4 Clinical Trial Details – PEG IFN alfa-2a/Hepatera Ltd
- Table 2.5 Clinical Trial Details – ATI-2173/Antios Therapeutics Inc
- Table 2.6 Clinical Trial Details – JNJ-73763989/Janssen Research & Development LLC
- Table 2.7 Clinical Trial Details – REP 2139-Ca/Replicor Inc
- Table 2.8 Clinical Trial Details – Lanreotide acetate/ASCIL Biopharm
- Table 2.9 Clinical Trial Details – Ropeginterferon alfa-2b/ PharmaEssentia
- Table 2.10 Clinical Trial Details – VIR-2218/Vir Biotechnology Inc
- Table 2.11 Clinical Trial Details – VIR-3434/Vir Biotechnology Inc
- Table 3.1 Regulatory Designations
- Table 4.1 Inactive Drugs
- Table 4.2 Discontinued Drugs
- List of Figures
- Figure 1.1 Number of Products under Development for Hepatitis D, 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for Hepatitis D, 2023
- Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Hepatitis D, 2023
- Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Hepatitis D, 2023
- Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Hepatitis D, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
